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Introduction
The most famous ‘proof’ in favor of CD19-targeted chimeric 
antigen receptor T (CAR-T) cell therapy is Emily Whitehead, 
the first child to have her own immune cells trained to fight 
cancer. It worked, and Emily has been cancer-free now for 
more than eight years.
CAR-T cell therapy is a groundbreaking treatment that 
has launched a new era in the treatment of hematologi-
cal malignancies.
Safety and efficacy evaluation of tisagenlecleucel 
(Kymriah®) in children was conducted in a clinical trial, 
ELIANA [1] and described in other studies [2, 3].
In 2017, Kymriah® became the first CAR-T cell therapy 
approved by the US Food and Drug Administration (FDA) 
for patients aged up to 25 years who suffer from B-cell 
precursor acute lymphoblastic leukemia that is refractory 
or in a second or subsequent relapse. In 2018, tisagenle-
cleucel was also approved by the European Commission.
CAR-T cell technology is an excellent example of cell 
gene therapy that is highly personalized to target an indi-
vidual patient’s disease [4].
To create CAR-T cells, a patient’s own T lymphocytes 
need ex vivo genetic manipulation. A gene encoding CAR 
anti-CD19 is introduced into the genome of T cell with the 
help of lentiviral vectors. After activation and expansion, 
ready-to-use CAR-T cells are obtained. When infused into 
the bloodstream, CAR-T cells are able to penetrate tissues, 
self-activate, amplify, eliminate neoplastic cells, and act 
long-term.
The first Polish patient was successfully treated with CAR-T 
cell therapy in November 2019 at the Department of Hema-
tology and Transplantology in Poznan. He was a 24-year-old 
male with refractory, early relapsed diffuse large B-cell lympho-
ma (DLBCL) after autologous stem cell transplantation [5, 6].
Also in November 2019, our center was approved by 
Novartis to become the first pediatric certified site for CAR-T 
cell therapy in Poland. The first implementation was per-
formed in March 2020 in an 11-year-old boy with multiply 
relapsed acute lymphoblastic leukemia.
Here, we present that patient’s clinical history, which 
eventually led to this innovative therapy.
Patient and procedure
The boy had been diagnosed with pre-B cell ALL (qualified 
later as intermediate risk) at the age of four, and he was 
treated according to the ALL IC BFM 2009 protocol from 
January 2013 to March 2015. His first relapse was confirmed 
12 months after the end of treatment (March 2016; late 
mixed relapse; bone marrow (BM) and central nervous 
system (CNS) affected) and managed with the IntRe ALL SR 
2010 protocol. Then, in December 2016, a first allogeneic 
hematopoietic stem cell transplantation from a matched sib-
ling donor was performed. A second relapse was diagnosed 
13 months later (January 2018, isolated marrow relapse). 
Treatment according to the IntRe ALL HR 2010 protocol 
(induction: HIB with bortezomib) was started, supplement-
ed with immunotherapy — blinatumomab. In April 2018, 
a second allo-HSCT, HLA-haploidentical (from the patient’s 
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father) was performed. A third relapse (isolated marrow) 
was confirmed eight months later in January 2019 This was 
treated with another HIB cycle. Unfortunately, minimal resid-
ual disease (MRD) was present both after two weeks and at 
the end of HIB. Considering the high risk of complications 
and possible resistance to chemotherapy, inotuzumab ozo-
gamicin was used in post-induction treatment. In July 2019, 
because of the persistent MRD, it was decided to administer 
blinatumomab. The therapy was complicated with severe 
neurotoxicity requiring the child’s transfer to the intensive 
care unit. After a month, despite 100% allogeneic chimerism, 
minimal residual disease using polymerase chain reaction 
(MRD-PCR) was still present at the level of 3 ×10–3. We decid-
ed to perform a stem cell boost from the same haploidentical 
donor. About 14.38 ×106 in vitro positively selected CD34/kg 
recipient’s body weight cells were transplanted, without 
previous conditioning and graft-versus-host disease (GvHD) 
prophylaxis. After the procedure, MRD was still present, 
forcing the use of three inotuzumab ozogamicin doses. Be-
cause of the multiply relapsed and refractory character of 
the leukemia, we decided to use CAR-T cell immunotherapy 
as a salvage treatment. Our patient was in a general good 
condition, sufficient to tolerate the therapy, without central 
nervous system involvement. BM biopsy carried out on 15 
October 2019 presented as follows: BM M1, chimerism 
100% allogeneic, MRD-PCR positive 3.0 ×10–4. A single dose 
of inotuzumab ozogamycin was given on 30 October 2019. 
Two weeks later, on 12 November, apheresis aimed to collect 
MNCs including T cells was performed successfully. At the 
time of apheresis, the patient’s WBC and T cells in peripheral 
blood exceeded minimal requirements [1.0 G/L WBC and 
0.3 G/L T cells]: 5.54 G/L and 1.835 G/L respectively. 5.93 
×109 T cells were collected (minimum 1 ×109 CD3+ cells). 
As a bridging therapy, the patient received inotuzumab ozo-
gamycin (0.5 mg/m2) on 13 January 2020.
BM biopsy before lymphodepleting chemotherapy (LDC) 
was performed on 20 February, revealing: bone marrow 
M1, chimerism 100% allogeneic, MRD-PCR positive below 
1 ×10–4. On four consecutive days, 25–28 February, LDC 
with cyclophosphamide 2 ×500 mg/m2 on days 1–2 and 
fludarabine 4 ×30 mg/m2 on days 1–4 was performed. On 
3 March, thawed 2.2 ×106 CAR-T cells/kg recipient’s body 
weight (Kymriah®, Novartis) were administered to the pa-
tient, following an antihistaminic premedication. Levetirac-
etam was used to prevent seizures. No typical side effects 
were observed during the hospitalization [7, 8]. One month 
post-transplant, a BM biopsy was carried out, revealing: 
M1 BM, chimerism 100% allogeneic (both from bone mar-
row and peripheral blood), MRD positive at 4 ×10–5. For 
the first time since the MRD measurement in the patient’s 
history, his MRD became negative on day +98 post infu-
sion (9 June 2020).
Now, after more than 11 months of infusion, the patient 
remains MRD-free and requires immunoglobulin (IVIG or 
SCIG) substitution due to most welcome prolonged B-cell 
aplasia [7]. His CAR-T cells remain present in peripheral 
blood; however the number has decreased from roughly 
2 cells/µL 5–7 months post infusion to 1.2/µL now (Table I).
A low level of MRD before LDC remains a challenge for 
physicians. In our hands, the maintenance administration 
Table I. CD19+, CD3+, white blood cells (WBC), chimeric antigen receptor T (CAR-T) cell counts and minimal residual disease using polymerase 
chain reaction (MRD-PCR) in patient monitored since Kymriah® infusion (measurements at time of lymphocytes subpopulation assessment)











0 3 March 2020 0 50 0.47 0.23 Nd <1 ×10–4*
7 days 10 March 2020 0 319 1.16 0.22 Nd Nd
13 days 16 March 2020 0 367 1.2 0.3 Nd Nd
20 days 23 March 2020 0 451 1.26 0.27 Nd Nd
27 days 30 March 2020 0 460 1.7 0.7 Nd Nd
1 month 3 April 2020 0 369 1.27 0.63 Nd 4 ×10–5
2 months 12 May 2020 0 1,180 2.19 0.58 Nd 1.2 ×10–5
3 months 9 June 2020 0 928 1.73 0.31 Nd Negative
4 months 1 July 2020 0 1,082 2.27 0.64 Nd Nd
5 months 11 August 2020 1 1,303 3.11 1.22 1.6 Nd
5.5 months 26 August 2020 0 1,337 2.76 0.82 2.6 Nd
6 months 10 September 2020 0 1,003 3.25 1.69 1.3 Negative
7 months 26 October 2020 0 1,489 3.11 1.21 1.7 Nd
9 months 7 December 2020 0 1,716 3.42 1.08 0.2 Nd
10 months 12 January 2021 0 2,025 3.61 0.82 1.2 Negative
*Bone marrow evaluation performed before lymphodepleting chemotherapy on 20 February 2020; ANC — absolute neutrophil count; nd — not done
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of inotuzumab ozogamycin proved to be effective before 
the final treatment.
Considering the patient’s medical history, the 11-month 
follow-up after CAR-T cells infusion allows us to look into 
the future with hope tempered by caution. The longer his 
CAR-T cells persist, the more chance he will have of achiev-
ing a long-awaited clinical cure.
Ongoing experience with CAR-T cell therapy tells us that 
this is not merely an example of fascinating bioengineering, 
but a realistic and promising therapy with an up to 90% re-
sponse rate with durable remissions in a population with 
refractory high-risk disease [7]. Nevertheless, Polish pa-
tients still cannot receive reimbursement for this treatment.
The implementation of CAR-T cell therapy in our pa-
tient was possible only thanks to the funds raised by the 
‘Na Ratunek Dzieciom z Choroba Nowotworowa’ founda-
tion and siepomaga.pl.
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